Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bextra “Dear Doctor” letter

Executive Summary

Pfizer/Pharmacia send "Dear Doctor" letter Nov. 13 alerting physicians to new warnings and a contraindication in Bextra labeling against use in patients with demonstrated allergic-type reactions to sulfonamides. The companies first alerted prescribers to the issue in October; revised labeling was approved by FDA Nov. 1 (1"The Pink Sheet" Nov. 11, p. 19)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS040791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel